Sarrade Thomas, Allodji Rodrigue, Ghannam Youssef, Auzac Guillaume, Everhard Sibille, Kirova Youlia, Peignaux Karine, Guilbert Philippe, Pasquier David, Racadot Séverine, Bourgier Céline, Ducornet Sandrine, André Fabrice, De Vathaire Florent, Rivera Sofia
Radiotherapy Department, Gustave Roussy, 94805 Villejuif, France.
Department of Radiation Oncology, Tenon Hospital, Paris Sorbonne University, 75020 Paris, France.
Cancers (Basel). 2023 Jan 25;15(3):751. doi: 10.3390/cancers15030751.
This article describes the methodology used and provides a characterization of the study population in CANTO-RT (CANcer TOxicities RadioTherapy). CANTO (NCT01993498) is a prospective clinical cohort study including patients with stage I-III BC from 26 French cancer centers. Patients matching all CANTO inclusion and exclusion criteria who received RT in one of the 10 top recruiting CANTO centers were selected. Individual full DICOM RT files were collected, pseudo-anonymized, structured and analyzed on the CANTO-RT/UNITRAD web platform. CANTO-RT included 3875 BC patients with a median follow-up of 64 months. Among the 3797 patients with unilateral RT, 3065 (80.4%) had breast-conserving surgery, and 2712 (71.5%) had sentinel node surgery. Tumor bed boost was delivered in 2658 patients (68.5%) and lymph node RT in 1356 patients (35%), including internal mammary chain in 844 patients (21.8%). Most patients (3691 (95.3%)) were treated with 3D conformal RT. Target volumes, organs at risk contours and dose/volume histograms were extracted after quality-control procedures. CANTO-RT is one of the largest early BC prospective cohorts with full individual clinical, biological, imaging and DICOM RT data available. It is a valuable resource for the identification and validation of clinical and dosimetric predictive factors of RT and multimodal treatment-related toxicities.
本文描述了所使用的方法，并对CANTO-RT（癌症放射治疗毒性）研究人群进行了特征描述。CANTO（NCT01993498）是一项前瞻性临床队列研究，纳入了来自26个法国癌症中心的I-III期乳腺癌患者。从10个招募患者最多的CANTO中心中，选取符合所有CANTO纳入和排除标准且接受放疗的患者。在CANTO-RT/UNITRAD网络平台上收集、伪匿名化、结构化并分析了个体完整的DICOM放疗文件。CANTO-RT纳入了3875例乳腺癌患者，中位随访时间为64个月。在3797例接受单侧放疗的患者中，3065例（80.4%）接受了保乳手术，2712例（71.5%）接受了前哨淋巴结手术。2658例患者（68.5%）接受了瘤床加量放疗，1356例患者（35%）接受了淋巴结放疗，其中844例患者（21.8%）接受了内乳链放疗。大多数患者（3691例（95.3%））接受了三维适形放疗。在质量控制程序后提取了靶区体积、危及器官轮廓和剂量/体积直方图。CANTO-RT是最大的早期乳腺癌前瞻性队列之一，可获得完整的个体临床、生物学、影像学和DICOM放疗数据。它是识别和验证放疗及多模式治疗相关毒性的临床和剂量学预测因素的宝贵资源。
